ORY-1001, an LSD1 inhibitor that has entered phase II clinical trials for AML, is an N-alkylated 2-PCPA derivative that possess an IC50 of 18 nM against LSD1 and selectivity over LSD2 and MAOs [116,117]. This evidence concerns the gene KDM1A and acute myeloid leukemia.